TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Visual Performance of the Vivity IOL in Post-myopic LASIK and PRK Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Subjects are eligible for the study if they meet the following criteria:~Note: Ocular criteria must be met in both eyes.~* Adult (at least 40 years) patients with a history of successful myopic LASIK/PRK and underwent bilateral uncomplicated cataract surgery with non-toric Alcon Vivity IOL at least 3 months before enrollment.~* Monocular BCDVA 20/25 or better.~* Patients may be \>2 weeks post-YAG capsulotomy for visually significant PCO.~* Post-operative sphere ≤0.50D, astigmatism ≤0.50D, and MRSE \< 0.75D.~Exclusion Criteria:~If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.~* Patients with corneal refractive surgery complications, significant ocular pathology, including moderate and severe dry eye, retina, optic nerve (including glaucoma) and corneal pathologies (e.g. corneal dystrophy, edema, significant scarring), limiting or affecting visual potential, in the opinion of the surgeon.~* Patients undergoing cataract removal with MIGS procedure.~* Patients with h/o ocular surgery, other than corneal refractive surgery, that may limit or affect visual potential in the opinion of the surgeon.~The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.~Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Patients with a history of successful myopic LASIK/PRK and underwent bilateral uncomplicated cataract surgery with non-toric Alcon Vivity IOL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Diagnosis of Pulmonary Embolism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinically suspected acute pulmonary embolism~* 18 years old or more~* D-dimers more than 500 or high clinical probability of pulmonary embolism according to the revised Geneva score~* Thoracic CT angiography performed within 24 hours~* Informed consent~Exclusion Criteria:~* - Contraindication to MRI (pace maker, claustrophobia, any implanted ferromagnetic foreign body)~* Obese patients too large to fit in MRI unit~* Allergy to gadolinium-containing contrast agent or to iodinated contrast media~* Renal insufficiency (clearance less than 30 ml/mn)~* Anticoagulation at a curative dose started more than 48 hours prior to MRI~* Life expectancy less than 3 months~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥8 years~2. Confirmed diagnosis of CF by consensus guidelines \[50\]~3. Diagnosis of CFRD based on American Diabetes Association and CFF criteria \[51\]~4. Admission for pulmonary exacerbation~Exclusion Criteria:~1. Known type 1 or type 2 diabetes, monogenic diabetes (MODY)~2. Critical illness requiring admission to the intensive care unit~3. Admission for indications other than pulmonary exacerbation (ex. Distal intestinal obstructive syndrome, surgery)~4. Pregnancy

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Insulin Pump and CGM (Type: EXPERIMENTAL): None
- Standard of Care and CGM (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Lutein on Visual Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women age 40-60 years~* Corrected Visual Acuity of 20/20 to 20/25~* MPOD 0.05- 0.30 OD units~* Must be able to give written informed consent in English~* BMI \< or = 30 kg/m2~* Subject is willing to maintain a habitual diet and physical activity patterns throughout the study period~Exclusion Criteria:~* Use of carotenoid, fish oil, or n-3 fatty acid supplements (within 2 months of study start)~* Ocular pathologies~* History of active small bowel disease or resection~* Uncontrolled hypertension~* Diabetes mellitus~* Pancreatic disease~* Pregnancy (or planning to become pregnant) or lactation~* Diseases that interfere with fat absorption~* Medication or supplements that contain a significant level of carotenoids~* Medications that interfere with fat absorption~* Use of drugs suspected of interfering with metabolism of blood clotting~* Chronic alcohol intake~* Stroke, head injury with loss of consciousness or seizures~* Severe Amblyopia resulting in visual acuity worse than 0.4 MAR~* Subject is a heavy smoker (\> 1 pack/day)~* A regular consumer of lutein rich foods or lutein supplements~* A regular consumer of foods high in DHA intake or DHA supplements~* Subject has donated more than 300 mL of blood during the last three months prior to screening

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Will be identical looking to treatment
- Lutein (Type: EXPERIMENTAL): 10 mg of FloraGLO Lutein

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Novel Treatments to Enhance Smoking Cessation Before Cancer Surgery: Effects on Smoking and Surgical Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 or older,~2. smoking 5 or more cigarettes per day, and~3. diagnosed with any type of head, neck, or thoracic cancer,~4. agreement on a 3-week pre-surgical tobacco intervention by both patient and surgeon.~Exclusion Criteria:~1. Unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, severe alcohol dependence, or dementia,~2. history of allergic reactions to adhesives,~3. females of childbearing potential who are pregnant, nursing, or not practicing effective contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Standard care and nicotine replacement therapy (Type: ACTIVE_COMPARATOR): standard care is 4 counseling sessions and nicotine replacement therapy
- standard care plus NRT plus contingency management (Type: EXPERIMENTAL): standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical signs and symptoms of heart failure according to the ESC guidelines~* Echocardiographic evidence of a preserved systolic left ventricular function (echocardiographic left ventricular ejection fraction \> 50%)~* Polysomnographic evidence of at least moderate sleep-disordered breathing: apnea-hypopnea index (AHI) \> 15 / h with ≥ 50% central events and with with a central AHI of ≥ 10/h (AHI based on total sleeping time, TST)~* BNP or NT-pro BNP ≥ 300 pg / ml~* NYHA class II or III~* Patient tolerates the ventilation treatment (1h sample ventilation)~* Stable drug therapy in the last 4 weeks prior to randomization (no iv diuretic therapy or increasing the dose of diuretics to ≥ 100%)~* Minimum age of patients of 18 years~* patient willing to undergo study procedures~* signed informed consent~Exclusion Criteria:~* Oxygen saturation (sO2) \<92% of the days in peace without O2 therapy, measured baseline (start time) in the pulse oximetry or polysomnography in a cape. BGA (the measurement must be max. Lie back 1 week)~* Patients, who have a risk professional with symptomatic sleep apnea~* Known COPD with FEV1 \<70%~* patients with NYHA stadium IV~* Advanced congenital heart defects~* pericardial diseases~* Existing PAP or bi-level therapy (including adaptive servo-ventilation) in the last 3 months~* Acute cardiac event in the last 3 months~* BMI ≥ 35kg / m²~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adaptive servo ventilation (ASV) (Type: EXPERIMENTAL): This group will receive ventilation therapy (AutoSet CS, ASV device)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: AVAD: Asthma With Small Airways Dysfunction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
General Inclusion Criteria:~* man or woman~* age ≥ 18 years~* asthma~* inform consent signed~* affiliated to health insurance~Specific inclusion criteria : asthma with proximal airways obstruction GROUP~* Maximal Voluntary Ventilation (MMV)\<80%~* MMV / Forced Vital Capacity (FVC)≤70%~* Carbon Monoxide Transfer Coefficient (KcO)\>80%~Specific inclusion criteria : asthma with small airways dysfunction GROUP~* Maximal Voluntary Ventilation (MMV)≥80%~* MMV / Vital Capacity(VC)\>70%~* Carbon Monoxide Transfer Coefficient (KcO)\>80%~General Exclusion Criteria:~* pregnant woman or breastfeeding~* patient participating to other biomedical research~* patient who have participated to other biomedical research within the past 3 months~* patient refusing to sign the inform consent~Specific exclusion criteria :~* Patient who stopped smoking since less than 12 months~* Pathological state related to obstructive distal airway damage~* Broncho-pulmonary infectious disease within the past 4 weeks~* Solid tumor curated by chemotherapy or chest radiotherapy~* Chronic respiratory disease~* Asthma exacerbation within the past 3 months~* Oral or systemic corticotherapy within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- asthma with proximal or diffuse lung damage (Type: ACTIVE_COMPARATOR): None
- asthma with small airway prevailing damage (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Ultrasound Guidance for Reduction of Pediatric Forearm Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who present to the Pediatric Emergency Department (PED) with a confirmed displaced forearm fracture that will require reduction by orthopedic surgery in the PED will be eligible for inclusion in this study.~Exclusion Criteria:~1. Patients with open fractures.~2. Patients with neurovascular compromise.~3. Unstable patients with life-threatening injuries who require ongoing resuscitation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: t

Study Arms:
- Fracture reduction without ultrasound (Type: ACTIVE_COMPARATOR): Fracture reduction as per standard of care involves closed fracture reduction without real-time imaging, or with c-arm or portable x-ray. Closed reduction of a fractured bone. Closed reduction is a procedure to set (reduce) a broken bone without surgery. This allows the bone to grow back together. It works best when it is done as soon as possible after the bone breaks.
- Fracture reduction with ultrasound (Type: EXPERIMENTAL): Ultrasound guided Fracture reduction involves closed fracture reduction with the use of real-time ultrasound imaging, prior to, during and after the reduction procedure. C-arm or portable x-ray may also be used as an adjunct.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Relation of Carotid Artery Plaque Inflammation, Covert Stroke and White Matter Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 60 or greater at time of enrollment~* Written informed consent from patient or legal representative~* Diagnosis of stroke or TIA made by a stroke specialist within 90 days and fulfilling the following criteria:~* A TIA must involve a focal speech/language, motor or visual deficit (transient monocular blindness, amaurosis fugax) referable to the distribution of a carotid artery and lasting less than 24 hours.~* A stroke consisting of deficits as noted above with duration greater than 24 hours and/or confirmed on cerebral imaging. Post event Modified Rankin Score of 2 or less.~* Stroke meets the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria for large artery atherosclerosis~* Carotid Doppler, CTA or MRA confirming the presence of bilateral atherosclerotic disease resulting in carotid stenosis of any degree. Stenosis will be measured following the method used in NASCET for CTA and MRA. Carotid Doppler measurements will follow the criteria defined by the Society for Ultrasound consensus conference.~* 12 lead ECG or Holter monitor confirming the absence of atrial fibrillation.~Exclusion Criteria:~* TIA or stroke in the vertebrobasilar system~* Index event was primary hemorrhage~* History of intermittent atrial fibrillation~* Cardiac source of embolus suspected as cause of index event (artificial valve, segmental or global LV dysfunction, congenital cardiac defect)~* Diagnosis of vasculitis, dissection, or non-atherosclerotic carotid disease (Ehlers-Danlos, Marfans)~* Sinovenous thrombosis, endocarditis or hypercoagulable state~* Pacemaker, ICD or other contraindications to MRI~* Diminished Kidney Function~* Contraindication to radiation exposure (eg: pregnancy)~* Severe Claustrophobia

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nuclear imaging (Type: EXPERIMENTAL): PET/CT imaging with F-18 fluorodeoxyglucose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Saccadic Reaction Time and Preterm Pre-eclampsia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria for cases:~1. Age ≥ 18 years~2. Confirmed diagnosis of pre-eclampsia, as defined by the International Society for the Study of Hypertension in Pregnancy (ISSHP)~3. Gestational age \< 35+0 weeks~4. Participant is willing and able to give informed consent~Inclusion criteria for controls:~1. Age ≥ 18 years~2. Absence of essential hypertension and pre-eclampsia or pregnancy-induced hypertension in current and previous pregnancies~3. Gestational age \< 35+0 weeks~4. Participant is willing and able to give informed consent~Exclusion Criteria:~1. Maternal neurological or psychiatric disorder (e.g. epilepsy, migraine, multiple sclerosis, depression, etc.)~2. Use of medication (other than vitamin supplements \[cases and controls\] and those for treatment or prevention of pre-eclampsia \[cases\]) during pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Preterm pre-eclampsia (cases) (Type: None): Pregnant patients diagnosed with pre-eclampsia prior to 35 weeks gestation
- Pregnant patients (controls) (Type: None): Age- and gestation-matched pregnant patients who are not suffering with pre-eclampsia, hypertensive disease or any other neuropsychiatric condition

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Laser - a New Possibility in Fertility Treatment - a Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. BMI : 18-32~2. long agonist/short antagonist IVF/intracytoplasmatic sperm injection (ICSI)treatment~3. 1-2 IVF/ICSI treatments without obtaining pregnancy.~4. signed consent~Exclusion Criteria:~1. uterine malformations~2. Uterine fibroids/polyps~3. need of an interpreter.~4. D.M, epilepsy, liver-kidney-heart disease~5. endometrial biopsy~6. cancer former cancer disease~7. acupuncture~8. metal in the body~9. suspicious naevi and tatoo´s

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Intervention (+ laser) (Type: EXPERIMENTAL): + laser therapy
- Non-intervention (- laser) (Type: PLACEBO_COMPARATOR): - laser

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Infusion for Pain Relief After Thoracotomy. A Randomized Controlled Trial.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective surgery~* Age 18-65 year~* ASA physical status 1-3~* Can use patient-controlled analgesia (PCA)~Exclusion Criteria:~* History of allergy to magnesium sulphate~* History of COPD, asthma or liver disease~* Serum creatinine \> 1.5 mg/dL~* History of CHF or atrioventricular conduction disturbance~* History of taking calcium channel blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline IV
- Magnesium sulphate (Type: EXPERIMENTAL): Magnesium sulphate 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Mechanical Chair for Treatment of Benign Paroxysmal Positional Vertigo (BPPV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All adult patients identified with BPPV through the Vanderbilt Balance Disorders Clinic or diagnosed with BPPV by Vanderbilt Otolaryngology will be eligible for inclusion.~Exclusion Criteria:~* Patients without BPPV. Also, the mechanical chair is contraindicated for for patients weighing over 330 lbs, patients presenting with unusual headache symptoms, uncontrolled high blood pressure or some associated neurological symptoms or any other atypical findings. It must not be used if the patient has undergone neurosurgery or cardiac surgery within the past month.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Repositioning (Type: ACTIVE_COMPARATOR): Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) without the mechanical chair.
- Mechanical Chair Repositioning (Type: EXPERIMENTAL): Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) with the mechanical chair.
- Sham Treatment (Type: SHAM_COMPARATOR): Participants randomly selected for the sham arm will undergo be strapped into the mechanical chair as for the treatment arm but will only undergo the test positions for BPPV-the Dix-Hallpike maneuver. No BPPV repositioning treatment will be completed at the first encounter. At the follow-up visit, standard BPPV treatments (canalith repositioning procedure) will be completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy